Sandoz launches new device for Omnitrope

September 30, 2013 4:59 PM

Sandoz announced last week the launch of SurePal™, a new delivery device to optimize the simplicity and security of administering Omnitrope human growth hormone for patients, their physicians and care givers.

SurePal has been CE marked in accordance with European Union (EU) laws on medical devices. The device is now available for patients in the United Kingdom and will be launched globally.

  • New device is a Sandoz innovation that will be available exclusively with Omnitrope
  • SurePal introduces simple and secure features that bring significant benefits to hGH patients
  • SurePal represents Sandoz’ latest commitment to hGH patients and the endocrinology community

SurePal has been CE marked in accordance with European Union (EU) laws on medical devices. The device is now available for patients in the United Kingdom and will be launched globally.

SurePal is a medical device for Omnitrope with cartridges that require no reconstitution, or priming, and a sliding injection button that requires minimum force to operate. Its safety features include non-interchangeable dose-specific cartridges, a dose memory function that remembers the patient’s daily dose and needle hider to reduce anxiety for patients afraid of needles. The new device has been specially designed by Sandoz to offer enhanced simplicity and security during treatment. In a usability study conducted in 106 patients in Germany and the U.S., 92 percent of respondents found an injection with SurePal very easy or easy to accomplish.

“SurePal is a Sandoz innovation that demonstrates our unwavering commitment to Growth Hormone patients,” said Mark McCamish, MD, Ph.D. Sandoz’ Head of Global Development for Biopharmaceuticals & Oncology Injectables. “Sandoz has invested significant time and resources to ensure that SurePal is a simple and secure solution that will provide major benefits to patients.”

“Patients treated with growth hormone therapy require an injection of hGH on a daily basis which requires significant commitment from the individual, parent or primary caregiver,” said Peter Laing, Paediatric Advanced Nurse Practitioner Endocrinology, Alder Hey Children’s NHS Foundation Trust. “Therefore ease of use and simplicity of the growth hormone device combined with features of added patient safety are essential to ensure good treatment outcomes and this is why I believe SurePal provides a quantum leap for hGH patients.”

 

Source: Sandoz press release

Leave a Reply

Twitter ID
(ID only. No links or "@" symbols)


Latest News on Biosimilar News

Share an Article?

Writing an article is not only a great way to share your knowledge, but it is also a great way to give back to the community.

We value all our contributors and if you have a website, we will surely give a link back to your site and products.
Wanna contribute?

Suggestions?

Biosimilar News was started for the people who are interested in this rapidly growing business area. So if you have suggestions or feedback on how we can improve, please let us know. If you want to see a specific topic covered, answer to a specific question, or anything else of this sort, just write us. We do our best to keep up!
Make a suggestion now!